Relmada Therapeutics (RLMD)
(Delayed Data from NSDQ)
$3.38 USD
-0.08 (-2.31%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $3.34 -0.04 (-1.18%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth C Momentum C VGM
Price, Consensus and EPS Surprise
RLMD 3.38 -0.08(-2.31%)
Will RLMD be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for RLMD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RLMD
Relmada Therapeutics (RLMD) Loses -43.35% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Relmada (RLMD) Up on Positive Data for Anti-Depressant Candidate
RLMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: NERV, RLMD Down on Updates, MRNA, NVAX's News & More
Relmada (RLMD) Lead Candidate Fails Late-Stage Depression Study
Other News for RLMD
Relmada jumps as Jefferies upgrades on a potential turnaround story
Morning Movers: Intel jumps after announcing AWS collaboration
Morning Movers: Intel jumps after announcing AWS collaboration
Relmada Therapeutics just upgraded at Jefferies, here's why
Insider Buying: CFO Maged Shenouda Acquires Shares of Relmada Therapeutics Inc (RLMD)